118 results about "Human papilloma virus infection" patented technology

Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.

The invention relates to a fluorescent PCR detection method for diagnosing human papilloma virus (HPV) infection, and a kit which is prepared according to the detection method and is used to detect HPV genotype of a DNA sample isolated from a patient body for diagnosing whether the HPV genotype belongs to one of the 24 types of human papilloma virus and determining as high risk, moderate high-risk and low risk, and belongs to the field of life science and technology. The method comprises: taking fluorogenic quantitative PCR as the technological basic polymerase chain reaction (PCR), employing the kit comprising multiple-type-directing forward primers, reverse primers and probes, and under specific PCR conditions and in a reaction tube, simultaneously detecting DNA of 24 types of HPV such as HPV 6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 83, MM4 and cp8304. The kit and the detection method helps to simply accurately rapidly detect DNA of multiple types of HPV and reduce the cost, and is effectively applicable to prevention and screening of cervical cancers.

The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.